Dipartimento di Scienze Chimiche e Geologiche, Cittadella Universitaria, 09042 Monserrato-Cagliari, Italy.
Dalton Trans. 2013 May 7;42(17):6161-70. doi: 10.1039/c2dt32252h. Epub 2012 Dec 3.
Triethylenetetramine (TETA) dihydrochloride, or trientine, is a therapeutic molecule that has long been used as a copper-chelating agent for the second-line treatment of patients with Wilson's disease. More recently, it has also been employed as an experimental therapeutic molecule in diabetes where it improves cardiac structure in patients with diabetic cardiomyopathy and left-ventricular hypertrophy. TETA is metabolized by acetylation, which leads to the formation of two main metabolites in humans and other mammals, monoacetyl-TETA (MAT) and diacetyl-TETA (DAT). These metabolites have been identified in the plasma and urine of healthy and diabetic subjects treated with TETA, and could themselves play a role in TETA-mediated copper chelation and restoration of physiological copper regulation in diabetes. In this regard, a potentiometric and spectrophotometric study of Cu(II)-complex formation equilibria of TETA, MAT and DAT is presented here, to provide a comprehensive evaluation of the stoichiometries of the complexes formed and of their relative stability constants. A potentiometric study has also been conducted on the corresponding Zn(II) complexes, to evaluate any possible interference with TETA-mediated Cu(II) binding by this second physiological transition-metal ion, which is present in similar concentrations in human plasma and which also binds to TETA. An ESI-MS study of these systems has both confirmed the complex formation mechanisms established from the potentiometric and spectrophotometric results, and in addition provided direct information on the stoichiometry of the complexes formed in solution. These data when taken together show that the 1 : 1 complexes formed with Cu(II) and Zn(II) have different degrees of protonation. The stability of the Cu(II) and Zn(II) complexes with the three ligands, evaluated by the parameters pCu and pZn, decreases with the introduction of the acetyl groups. Nevertheless the stability of Cu(II) complexes with MAT is sufficiently high to enable its participation in copper scavenging from the patient. A speciation study of the behavior of TETA and MAT with Cu(II) in the presence of Zn(II) at peri-physiological plasma concentrations is also presented. While Zn(II) did not hinder copper binding, the possibility is raised that prolonged TETA treatment could possibly alter the homeostatic regulation of this essential metal ion. The lack of reliable literature stability constants concerning the Cu(II) and Zn(II) interaction with the major transport proteins in plasma is also briefly considered.
三亚乙基四胺(TETA)二盐酸盐,或三亚乙基四胺,是一种治疗药物分子,长期以来一直被用作治疗威尔逊病患者的二线铜螯合剂。最近,它也被用作糖尿病的实验治疗药物分子,在糖尿病心肌病和左心室肥厚患者中,它可以改善心脏结构。TETA 通过乙酰化代谢,在人和其他哺乳动物中形成两种主要代谢物,单乙酰-TETA(MAT)和二乙酰-TETA(DAT)。在接受 TETA 治疗的健康和糖尿病受试者的血浆和尿液中已鉴定出这些代谢物,并且它们本身可能在 TETA 介导的铜螯合和糖尿病中恢复生理铜调节中发挥作用。在这方面,本文提出了 TETA、MAT 和 DAT 与 Cu(II) 配合物形成平衡的电位和分光光度研究,以全面评估形成的配合物的化学计量和相对稳定常数。还对相应的 Zn(II) 配合物进行了电位研究,以评估这种第二种生理过渡金属离子(在人血浆中存在相似浓度)对 TETA 介导的 Cu(II) 结合的任何可能干扰,该离子也与 TETA 结合。这些系统的 ESI-MS 研究不仅证实了从电位和分光光度结果确定的配合物形成机制,而且还提供了关于溶液中形成的配合物化学计量的直接信息。当这些数据放在一起时,表明与 Cu(II) 和 Zn(II) 形成的 1:1 配合物具有不同程度的质子化。通过 pCu 和 pZn 参数评估,三种配体与 Cu(II) 和 Zn(II) 形成的配合物的稳定性随乙酰基的引入而降低。然而,MAT 与 Cu(II) 形成的配合物的稳定性足够高,能够从患者中清除铜。还提出了在生理相关血浆浓度下存在 Zn(II)时 TETA 和 MAT 与 Cu(II) 行为的形态研究。虽然 Zn(II) 没有阻碍铜结合,但提出了一个可能性,即长期 TETA 治疗可能会改变这种必需金属离子的体内平衡调节。还简要考虑了缺乏关于 Cu(II) 和 Zn(II) 与血浆中主要转运蛋白相互作用的可靠文献稳定常数。